Items tagged with Diagnostics
QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of TB screening (post)
-- First-of-its-kind systematic review on the clinical relevance of test values from the QuantiFERON-TB Gold Plus TB1 and TB2 blood collection tubes has been published
-- Study including 4,050 subjects highlights the value of the TB2 tube and the detection of CD8 T-cell responses for immunocompromised patients, a key risk group for TB disease
-- Higher interferon-gamma production difference between TB2 and TB1 tubes in active TB compared to latent TB subjects suggests stronger CD8 T-cell response
Community-based testing boosts diagnosis of infectious TB, study finds (post)
An article published in Spotlight elaborates on a series of related trials called XACT, exploring community-based TB testing using battery-operated molecular tests.
Will fight TB with better diagnostic tools (post)
Rapid diagnosis and treatment are crucial in the fight against tuberculosis. But today's testing methods are not good enough. Tests based on blood biomarkers may be the solution.
Novel device holds promise for diagnosing TB in the 'missing millions' (post)
According to the World Health Organization, each year there are approximately three million undiagnosed cases of tuberculosis (TB) globally, which are characterized as the "missing millions." In a cutting-edge study, scientists have tested a diagnostic device using dielectrophoresis that holds promise for improving TB detection and treatment of patients in high-endemic, under-resourced areas. Bringing diagnostics to the patients who need it most will help meet global targets to reduce the burden of TB. The research results appear in The Journal of Molecular Diagnostics.
WHO issues rapid communication on use of targeted next-generation sequencing for diagnosis of drug-resistant TB (post)
25 July 2023 | Geneva --Targeted next generation sequencing (NGS) for the detection of drug-resistant TB is a new class of diagnostic technology. It provides an option for rapid and accurate genetic analysis and detection of mutations associated with resistance in a fraction of the time required for culture-based methods for detecting resistance. Various commercially available “End-to-End” tests for targeted NGS have become available in recent years that can detect resistance to multiple drugs simultaneously, provide rapid results with testing directly on patient samples, and have the potential to assimilate new information on genetic markers for resistance as they become known.
Public consultation for the Target Product Profile TB diagnostic tests for peripheral settings (post)
31 July 2023 | Geneva-- To inform research and development priorities for tuberculosis (TB) diagnostics and address unmet needs, the World Health Organization (WHO) is in the process of updating high-priority target product profiles (TPPs) for TB diagnostics. TPPs provide detailed technical specifications that are important to end-users (e.g. a test’s required performance) and operational characteristics to inform product manufacturers. Due to continuous developments in a TB diagnostic and treatment domains, there is ongoing need to regularly update TPPs in order to adapt them to an evolving context of a global TB control needs. Current update focuses on the TB diagnostic tests for peripheral settings.
Study identifies potential immune biomarker for pulmonary TB: a step towards early detection (post)
A recent study published in the Scientific Reports Journal examined immune responses in treatment-naive individuals with early-stage active pulmonary tuberculosis (TB) without clinical TB history. The researchers identified a potential immune biomarker associated with pulmonary TB in active patients compared to controls.
Mass screening for TB effective for asymptomatic older adults (post)
Mass screening is more effective than passive detection for identifying tuberculosis (TB) infection in older adults, primarily due to higher detection rates among asymptomatic individuals and those with limited health care access. These study results were published in Clinical Infectious Diseases.
Diagnostics to support the scaling up of shorter, safer TB regimens (post)
A comment, published in The Lancet Microbe, laid out key steps for expanding access to TB diagnostics to support the implementation of shorter, safer TB regimens demanded by the 1/4/6x24 Campaign.
Webinar: Time for $5 Campaign: Advocating for affordable GeneXpert tests and plans for the High-Level Meeting on TB (post)
Ahead of the High-Level Meeting on TB, Médecins Sans Frontières will host a webinar on 8 September 2023 to provide information about the next phase of the Time for $5 Campaign, calling on the diagnostics company Cepheid and its parent corporation Danaher to reduce the price of the GeneXpert test cartridge to $5.
Page 52 of 70 · Total posts: 0
←First 51 52 53 Last→